Orum Therapeutics sets public offering price at 20,000 won, below target range Orum Therapeutics announces lower-than-expected public offering price as subscription period approaches ...

To read more about the latest highlights related to the PDC market, get a snapshot of the key highlights entailed in the ...

Vertex Pharma has teamed up with Orum Therapeutics to develop a conditioning regimen, used to prepare patients to receive gene-editing medicines, that it hopes will offer a more tolerable ...

Bristol-Myers Squibb has signed another deal to build its capabilities in antibody-drug conjugates for cancer, paying $100 million upfront to take control of an Orum Therapeutics candidate with a ...

Bristol Myers Squibb is expanding its scope in cancer by acquiring rights to a Phase 1-ready Orum Therapeutics program that brings a new twist to antibody drug conjugates. The deal is the latest ...

You need to be a subscriber to view this content.